{"id":"pf-06410293","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting PDE4, the drug prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to elevated intracellular cAMP in immune and inflammatory cells. This elevation suppresses the production of pro-inflammatory cytokines and chemokines, thereby reducing inflammation. PDE4 inhibition has been explored for various inflammatory and immune-mediated conditions.","oneSentence":"PF-06410293 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:10.021Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT04230213","phase":"PHASE3","title":"A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-01-13","conditions":"Rheumatoid Arthritis","enrollment":455},{"nctId":"NCT02480153","phase":"PHASE3","title":"A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-06-25","conditions":"Rheumatoid Arthritis","enrollment":597},{"nctId":"NCT02572245","phase":"PHASE1","title":"A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-01","conditions":"Healthy Subjects","enrollment":164},{"nctId":"NCT02237729","phase":"PHASE1","title":"A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-09","conditions":"Healthy Subjects","enrollment":362},{"nctId":"NCT01870986","phase":"PHASE1","title":"Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-05","conditions":"Healthy","enrollment":210}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adalimumab-Pfizer","adalimumab-Pfizer"],"phase":"phase_3","status":"active","brandName":"PF-06410293","genericName":"PF-06410293","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"PF-06410293 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Psoriasis, Atopic dermatitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}